<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03659500</url>
  </required_header>
  <id_info>
    <org_study_id>HD Lab Frequency 1</org_study_id>
    <nct_id>NCT03659500</nct_id>
  </id_info>
  <brief_title>Clinical Outcomes and Costs of 4-Week Versus 6-Week Bloodwork for Patients on Hemodialysis</brief_title>
  <official_title>Clinical Outcomes and Costs of 4-Week Versus 6-Week Bloodwork for Patients on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this quality improvement study was to determine the effect of an
      institution-wide switch of routine bloodwork from four-week intervals to six-week intervals
      on the achievement of anemia and chronic kidney disease-mineral and bone disorder (CKD-MBD)
      targets for patients on chronic hemodialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale &amp; Objective: Routine bloodwork for patients on hemodialysis has both financial and
      opportunity costs, but there is little data on how the frequency of measurement affects
      patient outcomes. Our objective was to determine the effect of changing from routine
      bloodwork at four-week intervals to six-week intervals on the achievement of anemia and
      chronic kidney disease-mineral and bone disorder (CKD-MBD) targets.

      Study Design: Retrospective interrupted time series from June 1, 2012 to December 31, 2015.

      Setting &amp; Participants: Tertiary hospital in Ontario, Canada, that provides hemodialysis to
      350-400 adult patients.

      Quality Improvement Activities: Institution-wide switch of routine bloodwork from four-week
      intervals to six-week intervals on March 24, 2014.

      Outcomes: Proportion of patients who achieved recommended hemoglobin and phosphate targets.
      In a 252-day sub-analysis, we also calculated the cost-savings attributable to a change in
      laboratory testing frequency for hemoglobin, ferritin, iron saturation, calcium, and
      phosphate.

      Analytical Approach: Statistical Process Control to analyze variation in the clinical
      outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2012</start_date>
  <completion_date type="Actual">December 31, 2015</completion_date>
  <primary_completion_date type="Actual">December 31, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin target achievement</measure>
    <time_frame>650 days</time_frame>
    <description>Proportion of patients who achieved hemoglobin (10-12 g/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phosphate target achievement</measure>
    <time_frame>650 days</time_frame>
    <description>Proportion of patients who achieved phosphate (2.5-4.6 mg/dl)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Use of erythropoietin</measure>
    <time_frame>650 days</time_frame>
    <description>Proportion of patients on erythropoietin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium target achievement</measure>
    <time_frame>650 days</time_frame>
    <description>Proportion of patients with calcium (8.8-10.2 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTH target achievement</measure>
    <time_frame>650 days</time_frame>
    <description>Proportion of patients with PTH (94-462 pg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>650 days</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cost of laboratory tests</measure>
    <time_frame>650 days</time_frame>
    <description>Direct costs (in CAD) of hemoglobin ($8.27), ferritin ($14.48), iron saturation ($17.58), serum calcium ($2.59), and serum phosphate ($2.59) based on the Ontario Schedule of Benefits for Laboratory Services</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">400</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Four-week routine bloodwork</arm_group_label>
    <description>Routine bloodwork every 4-weeks (CBC, electrolytes, iron studies, calcium, phosphate, PTH) from June 1, 2012 to March 23, 2014</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Six-week routine bloodwork</arm_group_label>
    <description>Routine bloodwork every 6-weeks (CBC, electrolytes, iron studies, calcium, phosphate, PTH) from March 25, 2014 to December 31, 2015</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Four-week routine bloodwork</intervention_name>
    <description>Routine hemodialysis bloodwork done every 4 weeks</description>
    <arm_group_label>Four-week routine bloodwork</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Six-week routine bloodwork</intervention_name>
    <description>Routine hemodialysis bloodwork done every 6 weeks</description>
    <arm_group_label>Six-week routine bloodwork</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients on chronic hemodialysis at a regional hemodialysis program in Kingston,
        Ontario, Canada, from June 1, 2012 to December 31, 2015
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients who received chronic hemodialysis at the Kingston Health Sciences Center
             regional hemodialysis program

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel A Silver</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>September 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>September 3, 2018</last_update_submitted>
  <last_update_submitted_qc>September 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Samuel Silver</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

